Optimal clinical management of patients with primary myelofibrosis and post-essential thrombocythemia/polycythemia vera myelofibrosis is a challenge, given the typically advanced age of presentation and variability of the disease course and prognosis. Current medical therapeutic options have not demonstrated an impact on the disease course, which exceeds the palliation of disease-related extramedullary hematopoiesis and alleviation of cytopenias. In contrast, allogeneic stem cell transplantation (SCT) can lead to ‘cure’ but is limited due to patient's age or comorbidities. Currently, in patients, who are reasonable candidates, SCT (frequently with a reduced intensity conditioning regimen) is employed for intermediate- to high-risk disease. Current pharmaco-medical therapy is used as a bridge to transplant, or instead of transplant in poor transplant candidates. Pathogenetic insights, especially the discovery of the Janus kinase (JAK)2V617F mutation, have ushered in a host of new potential therapeutic agents that may augment the role of medical therapy. Similarly, the boundaries of transplantation continue to alter with strategies that decrease conditioning-related toxicity, improved antimicrobial prophylaxis and decreased graft-versus-host disease. The potential for continued improvements in both medical and transplant therapy suggests that for the immediate future the optimal choices for an individual patient will remain potentially volatile and present complex decisions.
Disease presentation and natural history
The BCR-ABL-negative myeloproliferative disorder of primary myelofibrosis (PMF)1 and the therapeutically indistinguishable advanced forms of essential thrombocythemia and polycythemia vera (that is, post-ET/PV myelofibrosis) is an extremely challenging disorder for both patients and clinicians. Indeed myelofibrosis is a very heterogeneous disorder with respect to age of onset, presenting features, phenotypic manifestations and prognosis. Therapeutic options for this debilitating and frequently fatal disorder range from observation and supportive care to medical therapy or even hematopoietic stem cell transplantation (SCT). Optimal management for an individual patient is a very complex decision-making process involving a thorough estimate of the individual's prognosis, the ability to tolerate a therapy and the risks and expectations of pharmaco-medical therapy, splenectomy or transplant-based therapy. Clinically meaningful advances in both medical and transplantation therapy continue to alter appropriate treatment choices in this disorder.
Patients presenting with myelofibrosis range from being asymptomatic (discovered on investigation for occult causes of leukocytosis or splenomegaly) to being severely debilitated. The median age at diagnosis is typically in the seventh decade of life (median 67 years),2 although patients may clearly present in the third to fifth decades of life.3, 4 Symptoms related to PMF can be broken down into one of three main categories: myeloproliferative, cytopenias and constitutional.
The natural history of myelofibrosis is quite variable as patients may experience morbidity or mortality directly from the clinical consequences of myelofibrosis or from transformation to acute myeloid leukemia (AML) (that is, PMF or post-ET/PV blast phase). Death, however, may well arise from the complications of myelofibrosis (that is, cytopenias) exacerbating underlying comorbidities such as coronary artery disease, or given the median age of the population afflicted, death from an unrelated comorbidity is always possible. Curative therapy in PMF is currently possible only with allogeneic hematopoietic SCT (AHSCT). AHSCT is, however, associated with a risk of mortality as well as morbidity that influences its application. Essential to the decision-making process in determining the appropriateness of low- or high-intensity therapies for PMF patients is the issue of prognosis. The prognosis for PMF patients is quite variable, with various prognostic features helpful to stratify the suspected outcomes in PMF patients. The various prognostic systems currently in use are discussed below (see Table 6 for comparison of PMF prognostic systems).
Current strategies for stem cell therapy
Stem cell transplantation can be performed with either autologous or allogeneic (syngeneic) stem cells. However, allogeneic SCT is the only curative treatment approach.
Only a few studies have investigated autologous SCT after high-dose chemotherapy in patients with myelofibrosis.5, 6, 7 In a pilot study, 21 patients received peripheral blood SCT after myeloablative conditioning with busulfan (16 mg per kg body weight). The median time of leukocyte and platelet engraftment was 21 days, however, graft failure was seen in 14% of the cases, and some patients had delayed engraftment up to 96 days for leukocyte recovery, and more than 200 days for platelet recovery. Three patients (14%) died from nonrelapse causes. Erythroid response without transfusion for more than 8 weeks was seen in 10 of 17 patients, and symptomatic splenomegaly improved in 7 of 10 patients. Four of eight patients showed some improvement of thrombocytopenia, and a reduction of bone marrow fibrosis was seen in 29% of the cases. In a small series of three patients who received autologous SCT after conditioning with treosulfan (42 g m−2 body surface), a prolonged leukocyte reconstitution of 28–38 days was seen, and a significant reduction of spleen size was noted.5 Overall, autologous SCT is a potential treatment approach that can relieve disease-related symptoms such as splenomegaly, but the curative potential is very unlikely.
Allogeneic SCT after standard myeloablative conditioning
Despite the increased use of allogeneic SCT in treatment of hematological malignancies, major concerns about performing this treatment approach in patients with PMF early arose due to the nature of bone marrow histopathology, which is distorted by fibrosis and it was hypothesized that this might lead to a higher risk of engraftment failure. The first small reports and case reports in the early 1990s, however, demonstrated that engraftment was feasible and regression of bone marrow fibrosis was achievable after myeloablative conditioning.8, 9 Furthermore, in relapsed patients after allografting, a graft-versus-myelofibrosis effect could be demonstrated by donor-lymphocyte infusions.10, 11 Larger retrospective studies including more than 50 patients with myelofibrosis were reported by Guardiola et al.12 in a combined analysis of European and American centers, and from Deeg et al.13 reporting the results of the Fred Hutchinson Cancer Center in Seattle. The latter study was recently updated and included 95 patients.14 In the retrospective European-American study, Guardiola et al.12 reported on 55 patients with myelofibrosis who underwent conventional allogeneic SCT. The median time from diagnosis to transplantation was 21 months (range, 2–266 months). Most of the patients received conditioning regimens, including total-body irradiation (TBI). Matched related donors were used in the majority of the patients (n=49). According to the Lille risk score, 76% had intermediate- or high-risk disease. Splenectomy prior to transplantation was done in 27 patients. Graft failure occurred in 9% of the patients and nonrelapse mortality at 1 year was 27%. The 5-year overall and disease-free survival were 47 and 39%, respectively. Patients with low risk according to the Lille score had better overall survival than patients with intermediate- or high-risk disease (85 versus 45–30%). In a multivariate analysis, hemoglobin <10 g per 100 ml, abnormal karyotype, high-risk disease according to the Lille score and presence of osteosclerosis had an adverse impact on survival.
The Seattle group recently updated its results of allogeneic SCT in patients with Philadelphia chromosome-negative myeloproliferative diseases.14 The study included 104 patients, and standard myeloablative conditioning was used in 95 patients. Most patients had myelofibrosis (n=62), or advanced ET (n=18), or PV (n=12). The median age was 49 years (range, 18–70 years), and stem cell donors were related (n=59), syngeneic (n=3) or unrelated donors (n=45). The conditioning regimens mainly consisted of TBI plus cyclophosphamide, or busulfan plus cyclophosphamide. Nonrelapse mortality at 5 years was 34%. The overall survival at 7 years was 61%. Improved survival in a multivariate analysis was seen for patients conditioned with a targeted busulfan/cyclophosphamide regimen, younger patients, patients with a low comorbidity score and patients with high platelet count at transplantation. The outcome of 320 patients with myelofibrosis after myeloablative conditioning reported to the International Bone Marrow Transplant Registry and to the National Marrow Donor Program showed a day 100 mortality of 22% after sibling transplantation, of 42% after matched unrelated donor transplantation and of 27% after alternative family donor transplantation, respectively. The overall survival at 5 years was 39, 31 and 31%, respectively. Patients with favorable status (Karnofsky index >90%, absence of blasts in peripheral blood) had survival of 81% at 5 years.15 The results of studies with standard myeloablative conditioning followed by allografting are listed in Table 1.12, 13, 14, 16, 17, 18, 19, 20, 21
Taking together the results of the published studies on conventional allogeneic SCT, the median age of the patients was between 38 and 54 years and significantly lower than the median age of about 67 years for patients with myelofibrosis at the time of diagnosis. The 5-year survival in the larger studies was 47 and 61%, respectively,12, 14 indicating the curative potential of standard myeloablative allograft. However, the nonrelapse mortality at 1 year ranged from 20 to 48% (Table 1), and one of the most significant prognostic factors for impaired survival was increasing age of the patient. In the European-American study, patients <45 years of age experienced 62% survival, whereas patients older than 45 years had a survival of only 14% mainly due to a higher treatment-related mortality22 In one study, SCT from an unrelated donor was associated with a worse outcome, while other studies did not show differences between related and unrelated SCT.13, 14, 22 Other factors for improved survival in multivariate analysis were conditioning with a targeting busulfan regimen,13, 14 high platelet count and low comorbidity index,14 low risk according to the Dupriez (Lille) score,12, 13 normal karyotype,12, 13 hemoglobin >10 g per 100 ml12 and non-osteosclerosis 12 (Table 2).
Allogeneic SCT after dose-reduced conditioning
Allogeneic SCT after standard myeloablative conditioning chemotherapy has been shown to be a curative treatment approach in patients with myelofibrosis, but the major limitation of this approach is that it can most reliably be performed only in younger patients with good performance status. The introduction of so-called ‘non-myeloablative’ or ‘dose-reduced’ or ‘toxicity-reduced’ conditioning regimen is based on the concept of shifting eradicating tumor cells from high-dose chemotherapy to the immunologically mediated graft-versus-tumor effect. The potential advantages are less treatment-related morbidity and mortality, and a broader application in elderly patients. Evidence for an immunologically mediated graft-versus-myelofibrosis effect comes from reports in relapsed patients after allogeneic SCT that show a remarkable reduction of bone marrow fibrosis after donor-lymphocyte infusion.10, 11 The feasibility of dose-reduced conditioning in patients with myelofibrosis was first reported in a small series of case reports.23, 24, 25, 26 In the two largest studies published so far, 27, 28 patients up to their seventh decade of age were included. In the German study,28 21 patients with a median age of 53 years (range, 32–63 years) were included. The conditioning regimen consisted of busulfan (10 mg per kg), fludarabine (180 mg m−2) and anti-thymocyte globulin (ATG; Fresenius, Graefelfing, Germany) (30 mg per kg for related and 60 mg per kg for unrelated donors), followed by SCT from related (n=8) or unrelated (n=13) donors. No primary graft failure was observed, and leukocyte and platelet engraftment were seen after a median of 16 days and 23 days, respectively. Complete donor chimerism was seen in 95% of patients at day +100. Acute graft-versus-host disease (GvHD) grade II–IV and grade III/IV was observed in 48 and 19% of the patients, respectively. Chronic GvHD occurred in 55% of the patients. Nonrelapse mortality was 16% at 1 year. After a median follow-up of 22 months (range, 4–59 months), the 3-year estimated overall and disease-free survival was 84%. The second study, from the MPD-Research Consortium, also included 21 patients, with a median age of 54 years (range, 27–68 years). Different conditioning regimens were used, including melphalan plus fludarabine, cyclophosphamide plus fludarabine, thiotepa plus fludarabine and TBI (2 Gy) in combination with fludarabine. All patients had intermediate or high risk according to the Lille score. One graft failure was observed. More than 95% donor chimerism was seen in 18 patients. Nonrelapse mortality was 10%, and overall 2-year survival was 87%. Table 3 shows other published results including three or more patients. The most commonly used regimens were busulfan/fludarabine based, and melphalan/fludarabine based. In comparison to the reported myeloablative transplantations (Table 1), the median age of the patients was more than 10 years older with 51–58 years. The nonrelapse mortality was lower than 20%, and overall survival after a relatively short follow-up was between 84 and 100%. Only in one small study,30 including nine patients, the nonrelapse mortality exceeded 40%, and the overall survival was only 56% at 1 year. A retrospective comparison between conventional and reduced-intensity conditioning regimen was performed in 26 patients from the Swedish Group for Myeloproliferative Disorders.29 Despite the fact that in the reduced-intensity group (n=10), the median age was 14 years older than in the myeloablative group (n=17), the nonrelapse mortality was lower in the reduced-intensity conditioning regimen than in the myeloablative group (10 versus 30%). In a prospective trial of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation, 104 patients with PMF and a median age of 55 years (range, 32–68) were included. The risk profile distribution was low risk with constitutional symptoms (18%), intermediate risk (n=58%) and high risk (n=19%). All but three patients received peripheral blood stem cells as graft source either from related (n=31) or unrelated donor (n=69). All but one (1%) patient showed leukocyte and platelet engraftment after a median of 18 and 21 days, respectively. The median duration of leukocyte aplasia was 9 days (range, 3–21). Acute GvHD grade II–IV occurred in 19%, and severe aGvHD grade III/IV in 7%, while chronic GvHD was seen in 32% of the patients. Nonrelapse mortality at 1 year was 19% (95% CI, 11–27%) and significantly lower for patients younger than 50 years of age (0 versus 27%; P=0.004) and for patients with low risk versus intermediate/high-risk disease (0 versus 27%; P=0.02). The cumulative incidence of relapse at 3 year was 29% (95% CI, 15–43%). After a median follow-up of 16 months, the 3-year overall and event-free survival was 70% (95% CI, 60–80%) and 55% (95% CI, 42–68%). Significant factors for improved 3-year overall and event-free survival were age <50 years (92 versus 62%, P=0.003 and 79% versus 46%, P=0.004), and low versus intermediate/high risk (100 versus 62%, P=0.01 and 72 versus 48%, P=0.02), while no impact on survival was seen for cytogenetic abnormalities, Janus kinase (JAK)2 mutation status and donor (related versus unrelated).31 In another single center study including 39 patients who received a dose-reduced conditioning consisting of thiotepa and cyclophosphamide favorable factors for improved survival were human leukocyte antigen-identical donor, Karnofsky-Index of 100%, time from diagnosis to transplantation of <1 year and previous splenectomy.32
Even if the follow-up of these studies is rather short, they demonstrated that reduced conditioning is effective and feasible with acceptable toxicity even in older patients.
Role of splenectomy prior transplantation
The role of pretransplant splenectomy remains controversial. The major concern about splenomegaly and allogeneic SCT is the risk of graft failure or delayed engraftment. Indeed, some reports have shown faster engraftment of splenectomized patients.12, 33 An analysis of 26 splenectomized patients showed less need for red blood cell or platelet transfusion in patients who underwent splenectomy prior transplantation, but the 3-year probability of survival did not differ significantly in comparison to non-splenectomized patients (73 versus 64%).34 Given the high risk of surgery-related morbidity and mortality, which exceeds 9%, the currently available data do not support a removal of the spleen prior allogeneic SCT.31, 35
The role of JAK2 mutation in the transplant setting
Recently the JAK2V617F mutation has been found in 35–50% of patients with myelofibrosis.36, 37 Based thereon, methods such as real-time PCR or pyrosequencing of blood granulocytes allow monitoring of treatment response at the molecular level.35, 36, 38, 39, 40 The predictive value of JAK2 mutation and outcome after allogeneic SCT remains to be determined. In a series of 30 patients, the JAK2 mutation status prior to transplantation did not appear to influence the outcome of allografting.41 JAK2 mutation screening with highly sensitive PCR should prove to add helpful information regarding the level of remission after allografting. For example the criteria for complete remission recently proposed by the International Working Group for myelofibrosis research and treatment (IWG-MRT) include disappearance of disease-related syndromes, peripheral blood levels of hemoglobin ⩾11 g per 100 ml and platelet counts ⩾100 × 109 per liter.42 However, after allogeneic SCT, these parameters are often influenced by GvHD, infections and poor graft function and they cannot be used exclusively as valid remission criteria. Moreover, on the other hand, normal blood counts and the disappearance of disease-related syndromes do not exclude residual disease, which might lead to clinical relapse. In the aforementioned study of 22 patients, 4 of 5 patients who never achieved JAK2 negativity still fulfilled during the entire follow-up all criteria for complete remission recently proposed by the IWG, suggesting a necessary role for JAK2 measurement to determine depth of remission status. After 22 allogeneic stem cell-transplantation procedures in 21 JAK2-positive patients with myelofibrosis, 78% became PCR negative. In 15 of 17 patients (88%), JAK2 remained negative after a median follow-up of 20 months. JAK2 negativity was achieved after a median of 89 days postallograft (range, 19–750 days). A significant inverse correlation was seen for JAK2 positivity and donor-cell chimerism (range, −0.91, P<0.001). To illustrate the practical value of detecting residual disease, in one case, residual JAK2-positive cells were successfully eliminated by donor–lymphocyte infusion,43 demonstrating that quantitative JAK2 measurement with highly sensitive PCR-technique after allogeneic SCT can help to guide adoptive immunotherapy strategies, such as donor–lymphocyte infusion, in order to obtain complete molecular remission.
Bone marrow fibrosis regression
The interactions between cytokine release, myeloid stroma and other bone marrow cells are only partially understood. Megakaryocytes are suggested to play a major role as a source of cytokine release.44, 45, 46, 47, 48 Furthermore, according to experimental studies, pathological interaction between megakaryocytes and neutrophils (emperipolesis) contributes to abnormal cytokine release.49 It sounds reasonable that replacement of the abnormal clonal hematopoietic cell population by allogeneic SCT would eliminate the stimulus for abnormal cytokine release. Indeed, several reports of allogeneic SCT after standard conditioning for myelofibrosis reported a reversal of bone marrow fibrosis between 6 and 12 months after transplantation.12, 13 More recently, the dynamics of successful reversal of bone marrow fibrosis after allografting were investigated.50, 51 In a series of 24 patients who underwent dose-reduced allografting with either fibrosis grade 2 (MF-2, n=13) or fibrosis grade 3 (MF-3) (n=11), after transplantation a complete (MF-0) or nearly complete (MF-1) regression of bone marrow fibrosis was seen in 59% at day +100, in 90% at day +180 and in 100% at day +360. No correlation between occurrence of acute GvHD and fibrosis regression on day +180 was seen.52 More recently, monitoring by magnetic resonance imaging (MRI) of the regression of myelofibrosis and osteosclerosis of the lumbar spine, pelvis and femora after allogeneic transplantation has been reported to assess the pattern and extent of residual fibrosis (advanced collagen) there.53
Broadening the applicability of cell therapy
Despite the recent advances in performing allogeneic SCT, toxicity, GvHD, as well as and infectious complications remain major issues. A lower intensity of the conditioning regimen reduces organ toxicity and the incidence of GvHD in comparison to the standard myeloablative regimen.54, 55 An effective strategy to prevent GvHD is T-cell depletion of the graft, which, however, is associated with an increased risk of relapse.56, 57 Polyclonal anti-human globulin (ATG) has been shown to reduce the risk of severe GvHD without an obvious increase in relapse.58 However, the role of any T-cell depleting strategy in allogeneic SCT for myelofibrosis has yet to be determined. Post-transplant adoptive immunotherapy with donor lymphocyte infusion can be given to prevent relapse in high-risk patients or as preemptive therapy in patients with noncomplete remission at a molecular level (for example, JAK2). Remission–induction therapy for advanced disease might improve the patient's conditioning by reducing disease-specific symptoms and therefore lowering treatment-related mortality following allogeneic SCT.
Currently available pharmaco-medical therapies for myelofibrosis
Currently available medical options are all considered in the armamentarium for myelofibrosis with the following caveats: (1) No medical therapy has been clearly proven to prolong survival, (2) no medical therapy has been proven to alter the natural history of the disorder, and given these first two caveats and (3) all current medical options are inherently palliative in intent. Given this latter fact, the benefit of utilizing currently available pharmaco-medical options must be weighted against their known toxicities. Since these medical options are explicitly chosen to palliate aspects of myelofibrosis, we will consider them in the context of the symptom they aim to palliate. For further details see Table 4).
In a meta-analysis of published data on the use of erythropoietin (Epo) in PMF, Rodriguez et al.70 reported a response rate of 33% with drug doses of up to 600 units per kg per week. Patients with endogenous serum-Epo levels of <125 mU ml−1 had the highest likelihood of response. In a more recent study, Cervantes et al.59 reported an overall response rate of 45% in 20 PMF patients treated with 30 000 units per week. A serum-Epo level of <125 U l−1 was again associated with a significantly higher likelihood of response in a multivariate analysis. Thus, Epo-treatment should be restricted to patients with anemia and inadequate Epo levels (that is, below the above-mentioned threshold. Darbopoietin has also been tried in a pilot study of 20 myelofibrosis patients with a 40% response rate (initial dose 150 μg per week increased to 300 μg per week), again with responses only in those patients with inadequate baseline serum Epo values.60
Androgens have been beneficial for the palliation of myelofibrosis-associated anemia.71 The most comprehensive analysis has been performed using 600 mg per day of danazol in which a 37% response rate was observed, with a median time to peak response of 5 months (range, 1–9 months). Patients who were anemic, yet not transfusion requiring were the most likely to respond.72 Currently, a trial of androgens is reasonable in palliating patients with myelofibrosis-associated anemia (after being satisfied that there is no occult prostatic cancer). There are no data comparing the palliative benefits of Epo to androgen therapy or using those agents in combination in PMF patients with anemia.
Tumor necrosis factor (TNF)-α is implicated in the pathogenesis of PMF-associated cytopenia as well as that of constitutional symptoms.73 Etanercept (Enbrel; Immunex, Seattle, WA, USA) is a TNF-α antagonist that has been shown to be helpful in abrogating TNF-α-associated disease features in rheumatoid arthritis. In a pilot study involving 22 patients with PMF, etanercept treatment (25 mg twice weekly, subcutaneous injections) for up to 24 weeks was well tolerated and produced 60% response in constitutional symptoms.74 However, only modest benefit was observed in either improving anemia or reducing splenomegaly (20%).
The diagnosis of extramedullary hematopoiesis (EMH) is based upon history, clinical examination and supportive radiographic studies (ultrasound, radionuclide, computed tomography and MRI). In the asymptomatic patient, there does not appear to be any advantage to uncovering occult EMH.
Hydroxyurea is an oral, well-tolerated, nonspecific myelosuppressive agent that can reliably control the leukocytosis as well as thrombocytosis associated with PMF.65 Treatment of leukocytosis is clinically useful only if it is extreme and symptomatic. We advise control of thrombocytosis in the presence of risk factors for thrombosis. Splenomegaly is not as responsive to hydroxyurea and might require a higher dose (2–3 g per day). Hydroxyurea therapy may potentially exacerbate anemia or thrombocytopenia (if present), but hydroxyurea-associated anemia might be ameliorated by the concomitant use of Epo therapy.
Alkylating agents have activity in PMF by causing a direct, nonspecific myelosuppression, and therefore may potentially palliate symptoms associated with myeloproliferation. A clinical trial was recently reported in PMF utilizing low doses of melphalan.67 Over a 7-year period, 104 patients with PMF were treated with 2.5 mg of oral melphalan three times a week with 66% of patients achieving a response after a median of 7 months of therapy. However, it was concerning that blastic transformation occurred in 26% of the study cohort.
Therapeutic splenectomy in PMF may result in extreme thrombocytosis, leukocytosis and accelerated hepatomegaly. Palliative benefit from 2-chlorodeoxyadenosine, a purine nucleoside analogue, has been reported to provide beneficial cytoreduction in such instances.75 The drug has been successfully used in PMF in either of two schedules commonly employed for this agent: 4 to 6 monthly cycles of treatment with either 0.1 mg per kg per day intravenously by continuous infusion for 7 days, or 5 mg m−2 intravenously over 2 hours for 5 consecutive days. In a recent update of our experience, responses were observed in 55, 50, 55 and 40% of patients for hepatomegaly, thrombocytosis, leukocytosis and anemia, respectively.67 Responses were frequently durable and lasted for a median of 6 months after discontinuation of treatment.
Therapy with interferon (IFN)-α has been utilized in patients with PMF based on its cytoreductive properties. IFN-α suppresses the proliferation of megakaryocytes and fibroblasts and has shown significant inhibition of collagen production in experimental models of myelofibrosis.76 Moreover, IFN-α inhibits in vitro and in vivo fibrogenic cytokines such as transforming growth factor β (TGF-β) and platelet-derived growth factor (PDGF), and in vitro IFN-α has shown an antiproliferative effect on hematopoietic progenitor stem cells.77 Aside from control of leukocytosis and/or thrombocytosis in patients exhibiting hyperproliferative features and sporadic instances of bone marrow fibrosis regression,78 clinical trials of IFN-α in PMF have been generally disappointing.79 Results have been equally underwhelming with IFN-γ,80 and pegylated IFN-α (PEG-IFN-α) 81 due to lack of tolerance and negligible response rates. In one study, subcutaneous PEG-IFN-α-2b (PEG-Intron) was administered weekly to 36 patients with BCR-ABL-negative MPDs, including 11 patients with PMF.80 None of the patients with PMF responded.
Medical therapy of PMF (post-ET/PV blast phase)
Blast phase of myelofibrosis occurs in approximately 10–15% of patients. In a recent series of 91 consecutive myelofibrosis patients who experienced blood pressure (BP), transformation was clinically heralded by organomegaly, worsening constitutional symptoms, anemia, thrombocytopenia and leukocytosis.82 Therapeutically these patients represent a very serious challenge. Leukemic Transformation (LT) was found to be fatal in 98% of patients after a median of 2.6 months (range, 0–24.2). Survival was equally poor regardless of whether patients received strictly supportive care, low intensity therapy (that is, low-dose cytarabine) or induction. Among 24 patients who received AML-like induction therapy (that is, cytarabine/idarubicin; mitoxantrone/etoposide and high-dose cytarabine), 42% had a brief return to chronic phase and endured a 33% treatment-related mortality. No complete remission was observed, and no activity was observed with the agent gemtuzumab. No patient was successfully brought to allogeneic transplant, suggesting that transplant should be considered well in advance of BP if desired. (further details are as per authors63, 66, 68, 69 given in Table 4).
Evolving pharmaco-medical therapy: what is next?
Improved understanding? Improved outcomes with targeted therapy?
Advances in the medical therapy of primary and post-ET/PV myelofibrosis will need to arise from the use of therapies specifically targeting the pathogenetic mechanisms of disease. Recent and ongoing trials have focused upon the cytokine milieu, the increased angiogenesis or the fibrosis inherent in this disorder. Further targeted strategies have focused upon tyrosine-kinase inhibition, aberrant farnesylation or DNA hypermethylation. Future strategies also hope to yield clinical benefit through the inhibition of the constitutively active JAK2-tyrosine-kinase mutation in the majority of MPD patients.
Targeting the aberrant cytokine milieu of myelofibrosis
The group of immunomodulatory cytokine inhibitors and antiangiogenic agents are collectively known as IMIDs. Initial pilot studies with thalidomide in PMF were dose escalating in nature beginning at doses of 100 mg per day.61 Subsequent low-dose (50 mg per day) thalidomide with a prednisone taper 62 resulted in significant responses observed for anemia (67%), thrombocytopenia (75%) and splenomegaly (33%), however without any definitive improvement in marrow or karyotypic abnormalities. Subsequently, lenalidomide (a second-generation, more potent cytokine inhibitor IMID) has been evaluated in 68 patients with symptomatic PMF with overall response rates of 22% for anemia, 33% for splenomegaly and 50% for thrombocytopenia,64 however with improved marrow histology in responders. Mirroring the activity of lenalidomide in del(5q) myelodysplastic syndrome, PMF patients with an abnormality of chromosome 5 seem to respond best to this agent.83 Given the promising results obtained with lenalidomide, a randomized, placebo-controlled, international clinical study to determine the activity of pomalidomide (20 000-fold more potent than thalidomide) in inhibiting TNF-α (with or without a prednisone taper) in PMF and post-ET/PV MF is currently under way with results eagerly anticipated (Table 5).
Additional angiogenesis inhibitors evaluated with minimal clinical activity and no impact on intramedullary manifestations of disease in myelofibrosis include both vatalanib (PTK787/ZK 222584: an oral inhibitor of the VEGF receptor-1 (VEGFR-1) and VEGFR-2 tyrosine kinases)92 and SU5416 (synthetic inhibitor of VEGFR-2 kit, and flt-3).93 The ability of the nonspecific ‘angiogenesis inhibitors’ such as thalidomide and lenalidomide to provide more profound responses (in the absence of improvements in angiogenesis) suggests that the clinical activity is independent of the inhibition of angiogenesis (further details as per authors 84, 85, 89, 90 in Table 5).
Inhibition of fibrogenesis
TGF-β1 plays a central role in the prominent bone marrow stromal reaction observed in patients with PMF. Pirfenidone (inhibitor of PDGF, TNF-α and TGF-β) was tested in a prospective study, but failed to show any significant clinical activity in PMF, in which 16 of 28 (57%) patients were withdrawn because of disease progression or drug intolerance, and only one patient had an improvement in anemia and splenomegaly.94 Similarly, clinical trials have been initiated based on preliminary data in a murine model of myelofibrosis suggesting that the proteasome-inhibitor bortezomib inhibits activation of the nuclear factor (NF)-κB pathway and decreases plasma concentration of TGF-β1, thus inhibiting the development of myelofibrosis.86 Several compounds that inhibit TGF-β1-mediated signaling are being explored preclinically in myelofibrosis, including GC-1008,88 AP-11014,95 LY580276 (IC50 175 nM),96 pyrazole 2 (IC50 18 nM),97 SB 505124 (IC50 47 nM)98 and SD-208.99
Inhibition of tyrosine kinases
The use of the tyrosine-kinase inhibitor imatinib mesylate for patients with PMF was based on its inhibitory activity against PDGF-mediated signaling and the reduction of bone marrow fibrosis and microvessel density observed in patients with chronic myeloid leukemia (CML), for which imatinib is a standard therapy.100 Results from all the phase II trials of imatinib in patients with PMF reported to date are modest to toxic.101, 102 Dasatinib (BMS-354825) is a dual Src- and Abl-kinase inhibitor, and a 300-fold more potent Abl-kinase inhibitor than imatinib,87 and effectively inhibits PDGF receptor-β (IC50 28 nM).102 Based on these preclinical data and on the results obtained with imatinib, clinical trials are underway.
Farnesyl transferase inhibitors
Tipifarnib (R115777), a non-peptidomimetic farnesyl-transferase inhibitor, was administered at 600 mg orally twice daily for 4 weeks of every 6-week cycle to eight patients with PMF.103 Two of them had a significant decrease in splenomegaly, one had normalization of white blood cell count and differential and one became transfusion independent.87 A second larger trial 104 was performed among 34 patients (with a lower 600 mg per day dosing). Tipifarnib resulted in little improvement in anemia, but achieved a clinically relevant decrease in organomegaly in 11 patients (33%)—splenomegaly in three, hepatomegaly in five and both in an additional three-, many of whom had previously failed hydroxyurea. Responses observed did not significantly correlate with reductions in bone marrow fibrosis, osteosclerosis, neo-angiogenesis or resolution of baseline karyotypic abnormalities. Whether this latter benefit is independent of tipifarnib-induced myelosuppression is unclear.
Targeting DNA hypermethylation
Aberrant cytosine phosphate guanine island hypermethylation in regulatory areas of tumor suppressor genes leading to inactivation is commonly encountered in human cancer.105 Methylation of p15INK4B, p16INK4A and the retinoic acid receptor β has been observed in advanced-stage PMF.106 Azacitidine and decitabine are DNA methyltransferase inhibitors that induce reactivation of methylated genes.91 Both agents are approved by the US Food and Drug Administration for the treatment of patients with MDS, and are currently being investigated in phase II studies in PMF.
Inhibition of JAK2
Although the currently identified molecular defects in MPD patients, such as the JAK2V617F,36, 37, 38, 40 do not yet fully explain many issues of MPD pathogenesis, they provide an exciting and hopefully more fruitful therapeutic target. There have already been multiple reports of agents in development, which have demonstrated the ability to inhibit the aberrant JAK2V617F, along with the wild type JAK2, such as TG101209,107 Go6976,108 erlotinib,109 MK0457110 and CEP-701.111 Intriguingly, in primary cells from wild-type JAK2 patient, who have the c-MPLW515L/K, growth inhibition can similarly be accomplished by JAK2 inhibitors, such as TG101209.107 These latter observations suggest the possibility that even in JAK2 wild-type MPD patients, a growth dependence on the JAK–signal transducers and activators of transcription (STAT) pathway may exist and agents targeting this pathway may be active regardless of the JAK2 mutation status. This hypothesis is further supported by the continual discovery of aberrations in this pathway, as in exon 12 of JAK2 gene in JAK2V617F-negative PV patients.112 Several clinical trials with these intriguing agents are scheduled to begin in 2007 and early 2008.
Who, when or how to transplant?
Since allogeneic SCT is increasingly used as curative treatment option even in older patients, the ever-present morbidity and mortality must be carefully balanced with patient life expectancy in order to offer optimal management. Several risk scores for myelofibrosis have been developed. The most widely used risk-assessment model is the Lille (or ‘Dupriez’) score,113 which distinguishes low, intermediate and high risk according to the hemoglobin (<10 g per 100 ml) and white blood cell count (<4 × 109 per liter or >30 × 109 per liter) with overall survival of 93 months, 26 months and 13 months, respectively. Another scoring system (Cervantes score)4 includes hemoglobin (<10 g per 100 ml), circulating blasts and constitutional symptoms, and it distinguishes low risk (none to one adverse factor: median survival, 176 months), and high risk (two to three adverse factors: median survival, 33 months). More recently, another risk-assessment score for patients with PMF was reported,114 which includes hemoglobin (<10 g per 100 ml), white blood cell count (<4 × 109 per liter or >30 × 109 per liter), platelet count (<100 × 109 per liter) and monocytes (⩾1 × 109 per liter). Patients with no risk factor had a median survival of 173 months, while patients with one risk factor had a median survival of 61 months, and those patients with two or more risk factors had a median survival of 26 months. A model from the Japanese Research Committee for Idiopathic Hematopoietic Disorders proposed four risk factors for myelofibrosis: male gender, circulating blasts ⩾1%, constitutional symptoms and hemoglobin <10 g per 100 ml. Patients with no or only one risk factor had a median survival of 292 months, while patients with two to four risk factors had a median survival of 66 months only.115 The only risk factor which includes age as risk factor is the Cologne score.116, 117
In Table 6 the different risk models are shown. This risk-assessment model might help to select patients for allogeneic SCT. However, other prognostic factors for decision making such as comorbidities, or cytogenetic abnormalities118 are not included in any of the models. Furthermore, risk features of one model cannot be translated into another model, for example, a patient with high risk according to the Cervantes score can have low risk according to the Lille score and vice versa. Therefore, given the low number of published results about allogeneic SCT (standard conditioning as well as reduced-intensity conditioning), all recommendations are based more on assumptions than on facts.
Age should not be a limiting factor for allogeneic SCT. More important are comorbidities such as cardiac or pulmonary diseases or other diseases, which can be summarized in a comorbidity score, which influences treatment outcome more significantly than the biological age.119 For patients with high risk according to the Cervantes score or intermediate/high risk according to the Lille score, allogeneic SCT should be evaluated. Since the life expectancy in industrialized countries is about 80 years for women and 75 years for men, patients up to the age of 70 years and older with low comorbidity score are suitable candidates for allogeneic SCT. Since patients with low-risk disease according to the Cervantes- or to the Lille score have a very low treatment-related mortality, at least in younger patients early transplantation should be considered. Unfortunately, all risk models are static models and do not take into account the dynamics of the disease. Therefore, our recommendation is to carefully monitor young patients with low-risk disease regarding the dynamics and to perform allogeneic SCT if clear signs of progress occur (decrease in hemoglobin, increase in lactate dehydrogenase, constitutional symptoms, rapid fibrosis in bone marrow, and so on), even if per definition the patients remained low-risk according to the above-mentioned risk scores.
The time point for performing allogeneic SCT is crucial. The so far limited literature suggests that transplantation in an early phase of the disease (for example, Lille risk score—low) resulted in a lower transplant-related morbidity and mortality and less risk of relapse. However, the risk of treatment-related mortality even in the era of reduced intensity conditioning for low-risk patients is still about 10% and should be balanced on an individual basis with survival time without early transplant. In contrast, transplantation in a late phase of the disease (Lille risk score—high, Cervantes high or transformation in acute leukemia) is associated with an increase risk of treatment-related mortality as well as risk of relapse. If the patient has almost developed AML, the chance of curing the disease by allogeneic SCT is considerably decreased. More work is necessary to develop dynamic risk models to determine the kinetics and dynamics of the progression in order to determine the optimal time point for allogeneic SCT with low treatment-related mortality and low risk of relapse.
It has been thought reasonable to perform allogeneic SCT with standard myeloablative conditioning in younger patients (<45 years) and dose-reduced conditioning in elderly patients (50–70 years). However, given the low mortality thus far reported after dose-reduced conditioning in comparison with standard conditioning, it seems questionable whether an age cut-off is wise. Studies in mice and later in humans provided evidence that curing hematological diseases by allogeneic SCT is not mainly related to high-dose conditioning regimen but rather to the immunologically mediated graft-versus-tumor effect of donor T cells. Since the toxicity of the conditioning regimen prior to allogeneic SCT contributes to treatment-related morbidity and mortality, an efficacious strategy to reduce treatment-related mortality might be to minimize toxicity. Such regimens were called non-myeloablative, but several dose-reduced regimens are still myeloablative. This approach can provided ensure allogeneic engraftment and complete donor chimerism by shifting tumor reduction from the preparative regimen to the action of immunocompetent donor cells to induce a graft-versus-myelofibrosis effect. Using modern methods such as highly sensitive JAK2 mutation screening after allografting, adoptive immunotherapy with donor lymphocyte infusion can be performed to eradicate minimal residual disease. Thus, for the majority of patients with intermediate risk, a dose-reduced conditioning is the regimen of choice, irrespectively of the age. Other factors which have to be taken into account to determine the intensity of the optimal conditioning regimen are (1) comorbidity index, which indicates how intensive a conditioning regimen is acceptable with regard to toxicity and risk of mortality for the patients and (2) the risk of relapse, which—if it is very high—requires a more intensified conditioning.
After many years of therapeutic fatalism, the introduction of low-intensity allogeneic SCT and new drugs as well as the discovery of JAK2V617F mutation offers a realistic curative chance and new hopes for molecular target therapy for patients with myelofibrosis. The choice of ‘optimal’ therapy in a patient with myelofibrosis is unlikely ever to be taken without thoughtful consideration and some consternation. Medical decision making will remain deciding at what point does the impact of medical therapy (with presumably less toxicity than SCT) exceed the net benefit of transplant. The intersection of these two forces will continue to change with, hopefully, decreased toxicity of transplant, and, hopefully, the ability of medical therapy to alter the natural history of the disease not just palliate symptomatology. Would we be able to reach a point where transplant is clearly the front-line therapy, or only medical therapy is considered? Perhaps, a scenario more likely will evolve that will mirror the therapy of CML: in essence, front-line therapy with medical therapy (perhaps a JAK2 inhibitor, although yet to be proven) with allogeneic SCT as second-line therapy for those with an inadequate response. Similar to CML, targeted therapies will probably play a larger role for those with a ‘chronic phase’ of the disease (that is, having arisen from the initiating genetic lesion likely). Those with more advanced phase (that is, equivalent to an accelerated or PMF-BP) will require transplantation initially or after a brief trial of a theoretically efficacious therapy. Similar to CML blast phase, we have clearly demonstrated PMF BP to be characterized by complex, and high-risk, karyotypic abnormalities, which are unlikely to be responsive to inhibition of primary targets. The ultimate goal for all patients should be cure, which can be achieved currently only by allogeneic SCT. Despite the marked improvement in performing allogeneic SCT, there is still a considerable risk of treatment-related morbidity and mortality. If palliation is the treatment aim, several drugs can relieve treatment-related symptoms, or cytopenia. In the near future, the treatment of myelofibrosis will be further improved by defining the optimal time point for allogeneic SCT by including remission-inducing drugs to make nontransplant candidates fit to become a transplant candidate, and reduce further treatment-related morbidity by developing effective post-transplant strategies, and by defining the role of the new JAK2-tyrosine-kinase inhibitors. We conclude, a more individualized, risk-adapted treatment approach including the available drug medication, low intensity allografting, as well as new JAK2 inhibitors will be the subject of the future of clinical research to cure more myelofibrosis patients with less risk from treatment: the present and future hold promise for patients and clinicians responding to the challenges of myelofibrosis.
Mesa RA, Verstovsek S, Cervantes F, Barosi G, Reilly JT, Dupriez B et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res 2007; 31: 737–740.
Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A . Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976–1995. Am J Hematol 1999; 61: 10–15.
Cervantes F, Barosi G, Hernandez-Boluda JC, Marchetti M, Montserrat E . Myelofibrosis with myeloid metaplasia in adult individuals 30 years old or younger: presenting features, evolution and survival. Eur J Haematol 2001; 66: 324–327.
Cervantes F, Barosi G, Demory JL, Reilly J, Guarnone R, Dupriez B et al. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol 1998; 102: 684–690.
Fruehauf S, Buss EC, Topaly J, Kreipe HH, Ho AD . Myeloablative conditioning in myelofibrosis using i.v. treosulfan and autologous peripheral blood progenitor cell transplantation with high doses of CD34+ cells results in hematologic responses—follow-up of three patients. Haematologica 2005; 90: ECR08.
Anderson JE, Tefferi A, Craig F, Holmberg L, Chauncey T, Appelbaum FR et al. Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis. Blood 2001; 98: 586–593.
Ngirabacu MC, Ravoet C, Dargent JL, Meuleman N, Ahmad I, Ysebrant L et al. Long term follow-up of autologous peripheral blood stem cell transplantation in the treatment of a patient with acute panmyelosis with myelofibrosis. Haematologica 2006; 91 (12 Suppl): ECR53.
Dokal I, Jones L, Deenmamode M, Lewis SM, Goldman JM . Allogeneic bone marrow transplantation for primary myelofibrosis. Br J Haematol 1989; 71: 158–160.
Creemers GO, Lowenberg B, Hagenbeek A . Allogeneic bone marrow transplantation for primary myelofibrosis. Br J Haematol 1992; 82: 772–773.
Byrne JL, Beshti H, Clark D, Ellis I, Haynes AP, Das-Gupta E et al. Induction of remission after donor leucocyte infusion for the treatment of relapsed chronic idiopathic myelofibrosis following allogeneic transplantation: evidence for a ‘graft vs myelofibrosis’ effect. Br J Haematol 2000; 108: 430–433.
Cervantes F, Rovira M, Urbano-Ispizua A, Rozman M, Carreras E, Montserrat E . Complete remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic transplantation: demonstration of a graft-versus-myelofibrosis effect. Bone Marrow Transplant 2000; 26: 697–699.
Guardiola P, Anderson JE, Bandini G, Cervantes F, Runde V, Arcese W et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood 1999; 93: 2831–2838.
Deeg HJ, Gooley TA, Flowers ME, Sale GE, Slattery JT, Anasetti C et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 2003; 102: 3912–3918.
Kerbauy DM, Gooley TA, Sale GE, Flowers ME, Doney KC, Georges GE et al. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplant 2007; 13: 355–365.
Ballen K, Sobocinski M, Zhang MJ, Arora M, Horowitz M, Giralt S . Outcome of bone marrow transplantation for myelofibrosis. Blood 2005; 106: Abstract no. 170.
Singhal S, Powles R, Treleaven J, Pollard C, Lumley H, Mehta J . Allogeneic bone marrow transplantation for primary myelofibrosis. Bone Marrow Transplant 1995; 16: 743–746.
Anderson JE, Sale G, Appelbaum FR, Chauncey TR, Storb R . Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis. Br J Haematol 1997; 98: 1010–1016.
Daly A, Song K, Nevill T, Nantel S, Toze C, Hogge D et al. Stem cell transplantation for myelofibrosis: a report from two Canadian centers. Bone Marrow Transplant 2003; 32: 35–40.
Mittal P, Saliba RM, Giralt SA, Shahjahan M, Cohen AI, Karandish S et al. Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia. Bone Marrow Transplant 2004; 33: 1005–1009.
Ditschkowski M, Beelen DW, Trenschel R, Koldehoff M, Elmaagacli AH . Outcome of allogeneic stem cell transplantation in patients with myelofibrosis. Bone Marrow Transplant 2004; 34: 807–813.
Przepiorka D, Giralt S, Khouri I, Champlin R, Bueso-Ramos C . Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases. Am J Hematol 1998; 57: 24–28.
Guardiola P, Anderson JE, Gluckman E . Myelofibrosis with myeloid metaplasia. N Engl J Med 2000; 343: 659 (Letter).
Hessling J, Kröger N, Werner M, Zabelina T, Hansen A, Kordes U et al. Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2002; 119: 769–772.
Devine SM, Hoffman R, Verma A, Shah R, Bradlow BA, Stock W et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood 2002; 99: 2255–2258.
Greyz N, Miller WE, Andrey J, Mason J . Long-term remission of myelofibrosis following nonmyeloablative allogeneic peripheral blood progenitor cell transplantation in older age: the Scripps Clinic experience. Bone Marrow Transplant 2004; 34: 273–274.
Tanner ML, Hoh CK, Bashey A, Holman P, Sun C, Broome HE et al. FLAG chemotherapy followed by allogeneic stem cell transplant using nonmyeloablative conditioning induces regression of myelofibrosis with myeloid metaplasia. Bone Marrow Transplant 2003; 32: 581–585.
Rondelli D, Barosi G, Bacigalupo A, Prchal JT, Popat U, Alessandrino EP et al. Myeloproliferative Diseases-Research Consortium. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood 2005; 105: 4115–4119.
Kröger N, Zabelina T, Schieder H, Panse J, Ayuk F, Stute N et al. Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. Br J Haematol 2005; 128: 690–697.
Merup M, Lazarevic V, Nahi H, Andreasson B, Malm C, Nilsson L et al. Swedish Group for Myeloproliferative Disorders. Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens. Br J Haematol 2006; 135: 367–373.
Snyder DS, Palmer J, Stein AS, Pullarkat V, Sahebi F, Cohen S et al. Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis. Biol Blood Marrow Transplant 2006; 12: 1161–1168.
Kröger N, Holler E, Kobbe G, Bornhäuser M, Schwerdtfeger R, Nagler A et al. Dose-reduced conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis. Blood 2007; 110: Abstract no. 683.
Bacigalupo A, Dominetto A, Pozzi S, Piaggio G, van Lint MT, Zupo S et al. Allogeneic hematopoietic stem cell transplant for patients with idiopathic myelofibrosis using a reduced intensity thiotepa based conditioning regimen. Blood 2007; 110: Abstract no. 684.
Li Z, Deeg HJ . Pros and cons of splenectomy in patients with myelofibrosis undergoing stem cell transplantation. Leukemia 2001; 15: 465–467.
Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN . Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood 2000; 95: 2226–2233.
Barosi G, Ambrosetti A, Centra A, Falcone A, Finelli C, Foa P et al. Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia. Blood 1998; 91: 3630–3636.
Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–1061.
Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387–397.
James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144–1148.
Jones AV, Silver RT, Waghorn K, Curtis C, Kreil S, Zoi K et al. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood 2006; 107: 3339–3341.
Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779–1790.
Ditschkowski M, Elmaagacli AH, Trenschel R, Steckel NK, Koldehoff M, Beelen DW . No influence of V617F mutation in JAK2 on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis. Biol Blood Marrow Transplant 2006; 12: 1350–1351.
Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia: On behalf of the IWG for myelofibrosis research and treatment (IWG-MRT). Blood 2006; 108: 1497–1503.
Kröger N, Badbaran A, Holler E, Hahn J, Kobbe G, Bornhaeuser M et al. Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood 2007; 109: 1316–1321.
Thiele J, Kvasnicka HM, Fischer R, Diehl V . Clinicopathological impact of the interaction between megakaryocytes and myeloid stroma in chronic myeloproliferative disorders: a concise update. Leuk Lymphoma 1997; 24: 463–481.
Wang JC, Chang TH, Goldberg A, Novetsky AD, Lichter S, Lipton J . Quantitative analysis of growth factor production in the mechanism of fibrosis in agnogenic myeloid metaplasia. Exp Hematol 2006; 34: 1617–1623.
Katoh O, Kimura A, Itoh T, Kuramoto A . Platelet derived growth factor messenger RNA is increased in bone marrow megakaryocytes in patients with myeloproliferative disorders. Am J Hematol 1990; 35: 145–150.
Le Bousse-Kerdiles MC, Martyre MC, French INSERM research network on Idiopathic Myelofibrosis. Involvement of the fibrogenic cytokines, TGF-beta and bFGF, in the pathogenesis of idiopathic myelofibrosis. Pathol Biol (Paris) 2001; 49: 153–157.
Martyré MC . Critical review of pathogenetic mechanisms in myelofibrosis with myeloid metaplasia. Curr Hematol Rep 2003; 2: 257–263.
Centurione L, Di Baldassarre A, Zingariello M, Bosco D, Gatta V, Rana RA et al. Increased and pathologic emperipolesis of neutrophils within megakaryocytes associated with marrow fibrosis in GATA-1(low) mice. Blood 2004; 104: 3573–3580.
Thiele J, Kvasnicka HM, Dietrich H, Stein G, Hann M, Kaminski A et al. Dynamics of bone marrow changes in patients with chronic idiopathic myelofibrosis following allogeneic stem cell transplantation. Histol Histopathol 2005; 20: 879–889.
Ni H, Barosi G, Rondelli D, Hoffman R . Studies of the site and distribution of CD34+ cells in idiopathic myelofibrosis. Am J Clin Pathol 2005; 123: 833–839.
Kröger N, Thiele J, Kobbe G, Schwerdtfeger R, Bornhäuser M, Bethge W et al. Rapid Regression of bone marrow fibrosis after dode-reduced allogeneic stem cell transplantation. Exp Hematol 2007; 35: 1719–1722.
Sale GE, Deeg HJ, Porter BA . Regression of myelofibrosis and osteosclerosis following hematopoietic cell transplantation assessed by magnetic resonance imaging and histologic grading. Biol Blood Marrow Transplant 2006; 12: 1285–1294.
Mielcarek M, Martin PJ, Leisenring W, Flowers ME, Maloney DG, Sandmaier BM et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102: 756–762.
Perez-Simon JA, Diez-Campelo M, Martino R, Brunet S, Urbano A, Caballero MD et al. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation. Br J Haematol 2005; 130: 394–403.
Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979; 300: 1068–1073.
Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED . Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981; 304: 1529–1533.
Kröger N, Zabelina T, Krüger W, Renges H, Stute N, Rischewski J et al. In-vivo T-cell depletion with pretransplant anti-thymocyte globulin reduces graft versus host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors. Bone Marrow Transplant 2002; 29: 683–689.
Cervantes F, Alvarez-Larran A, Hernandez-Boluda JC, Sureda A, Torrebadell M, Montserrat E . Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. Br J Haematol 2004; 127: 399–403.
Cervantes F, Alvarez-Larran A, Hernandez-Boluda JC, Sureda A, Granell M, Vallansot R et al. Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia. Br J Haematol 2006; 134: 184–186.
Barosi G, Grossi A, Comotti B, Musto P, Gamba G, Marchetti M . Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2001; 114: 78–83.
Mesa RA, Steensma DP, Pardanani A, Li CY, Elliott M, Kaufmann SH et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003; 101: 2534–2541.
Wickramasinghe SN, Peart S, Gill DS . Alpha-interferon in primary idiopathic myelofibrosis (letter). Lancet 1987; 2: 1524–1525.
Tefferi A, Cortes J, Verstovsek S, Mesa RA, Thomas D, Lasho TL et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006; 108: 1158–1164.
Lofvenberg E, Wahlin A . Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. Eur J Haematol 1988; 41: 375–381.
Manoharan A, Pitney WR . Chemotherapy resolves symptoms and reverses marrow fibrosis in myelofibrosis. Scand J Haematol 1984; 33: 453–459.
Petti MC, Latagliata R, Spadea T, Spadea A, Montefusco E, Aloe Spiriti MA et al. Melphalan treatment in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2002; 116: 576–581.
Najean Y, Rain JD . Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group. Blood 1997; 89: 2319–2327.
Tefferi A, Silverstein MN, Li CY . 2-Chlorodeoxyadenosine treatment after splenectomy in patients who have myelofibrosis with myeloid metaplasia. Br J Haematol 1997; 99: 352–357.
Rodriguez JN, Martino ML, Dieguez JC, Prados D . rHuEpo for the treatment of anemia in myelofibrosis with myeloid metaplasia. Experience in 6 patients and meta-analytical approach. Haematologica 1998; 83: 616–621.
Besa E, Nowell P, Geller N, Gardner F . Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: the value of chromosomal studies in prediciting response and survival. Cancer 1982; 49: 308.
Cervantes F, Alvarez-Larran A, Domingo A, Arellano-Rodrigo E, Montserrat E . Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. Br J Haematol 2005; 129: 771–775.
Battegay EJ, Raines EW, Colbert T, Ross R . TNF-alpha stimulation of fibroblast proliferation. Dependence on platelet-derived growth factor (PDGF) secretion and alteration of PDGF receptor expression. J Immunol 1995; 154: 6040–6047.
Steensma DP, Mesa RA, Li CY, Gray L, Tefferi A . Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study. Blood 2002; 99: 2252–2254.
Faoro LN, Tefferi A, Mesa RA . Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia. Eur J Haematol 2005; 74: 117–120.
Huang J, Xu J . Proliferation of human marrow fibroblasts suppressed synergistically by interferon alpha and TGF-β1 in vitro. Blood 2003; 102: Abstract no. 5077.
Carlo-Stella C, Cazzola M, Gasner A, Barosi G, Dezza L, Meloni F et al. Effects of recombinant alpha and gamma interferons on the in vitro growth of circulating hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM) from patients with myelofibrosis with myeloid metaplasia. Blood 1987; 70: 1014–1019.
Dalla KP, Zeigler ZR, Shadduck RK . Alpha-Interferon in myelofibrosis: a case report (see comments). Br J Haematol 1994; 86: 654–656.
Tefferi A, Elliot MA, Yoon SY, Li CY, Mesa RA, Call TG et al. Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia. Blood 2001; 97: 1896.
Heis-Vahidi-Fard N, Forberg E, Eichinger S, Chott A, Lechner K, Gisslinger H . Ineffectiveness of interferon-gamma in the treatment of idiopathic myelofibrosis: a pilot study. Ann Hematol 2001; 80: 79–82.
Verstovsek S, Lawhorn K, Giles F, Cortes J, Thomas D, Garcia-Manero G et al. PEG-Intron for Myeloproliferative Diseases: an update of ongoing phase II study. Blood 2004; 104: Abstract no. 1517.
Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A . Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood 2005; 105: 973–977.
Tefferi A, Lasho TL, Mesa RA, Pardanani A, Ketterling RP, Hanson CA . Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions. Leukemia 2007; 21: 1827–1828.
Schafer PH, Gandhi AK, Loveland MA, Chen RS, Man HW, Schnetkamp PP et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther 2003; 305: 1222–1232.
Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000; 60: 2178–2189.
Wagner-Ballon O, Gastinne T, Tulliez M, Lacout C, Pisani D, Chagraoui H et al. Proteasome inhibitor bortezomib can inhibit bone marrow fibrosis development in a murine model of myelofibrosis. Blood 2005; 106: Abstract no. 2582.
Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004; 47: 6658–6661.
Yingling JM, Blanchard KL, Sawyer JS . Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov 2004; 3: 1011–1022.
Cardones AR, Banez LL . VEGF inhibitors in cancer therapy. Curr Pharm Des 2006; 12: 387–394.
O’Brien S, Kipps TJ, Faderl S, Crump M, Keating MJ, Anderson B et al. A phase I trial of the small molecule Pan-Bcl-2 family inhibitor GX15-070 administered intravenously (IV) every 3 weeks to patients with previously treated chronic lymphocytic leukemia (CLL). Blood 2005; 106: Abstract no. 446.
Issa JP, Gharibyan V, Cortes J, Jelinek J, Morris G, Verstovsek S et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 2005; 23: 3948–3956.
Giles FJ, List AF, Carroll M, Cortes JE, Valickas J, Chen BL et al. PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia. Leu Res 2007; 31: 891–897.
Giles FJ, Cooper MA, Silverman L, Karp JE, Lancet JE, Zangari M et al. Phase II study of SU5416—a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor—in patients with refractory myeloproliferative diseases. Cancer 2003; 97: 1920–1928.
Mesa RA, Tefferi A, Elliott MA, Hoagland HC, Call TG, Schroeder GS et al. A phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasia. Br J Haematol 2001; 114: 111–113.
Schlingensiepen KH, Bischof A, Egger T, Hafner M, Herrmuth H, Jachimczak P et al. The TGF-Beta1 antisense oligonucleotide AP 11014 for the treatment of non-small cell lung, colorectal and prostate cancer: preclinical studies. J Clin Oncol 2004; 22 (14S): 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition); Abstract no. 3132.
Sawyer JS, Beight DW, Britt KS, Anderson BD, Campbell RM, Goodson Jr T et al. Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. Bioorg Med Chem Lett 2004; 14: 3581–3584.
Gellibert F, Woolven J, Fouchet MH, Mathews N, Goodland H, Lovegrove V et al. Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors. J Med Chem 2004; 47: 4494–4506.
Callahan JF, Burgess JL, Fornwald JA, Gaster LM, Harling JD, Harrington FP et al. Identification of novel inhibitors of the transforming growth factor beta1 (TGF-beta1) type 1 receptor (ALK5). J Med Chem 2002; 45: 999–1001.
Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R et al. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 2004; 64: 7954–7961.
Kvasnicka HM, Thiele J . Bone marrow angiogenesis: methods of quantification and changes evolving in chronic myeloproliferative disorders. Histol Histopathol 2004; 19: 1245–1260.
Tefferi A, Mesa RA, Gray LA, Steensma DP, Camoriano JK, Elliott MA et al. Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia. Blood 2002; 99: 3854–3856.
Cortes J, Ault P, Koller C, Thomas D, Ferrajoli A, Wierda W et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood 2003; 101: 4714–4716.
Cortes J, Albitar M, Thomas D, Giles F, Kurzrock R, Thibault A et al. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 2003; 101: 1692–1697.
Mesa RA, Camoriano JK, Geyer SM, Wu W, Kaufmann SH, Rivera CE et al. A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia. Leukemia 2007; 21: 1964–1970.
Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP . Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998; 72: 141–196.
Martyre MC, Steunou V, Le Bousse-Kerdiles MC, Wietzerbin J . Lack of alteration in GATA-1 expression in CD34+ hematopoietic progenitors from patients with idiopathic myelofibrosis (comment). Blood 2003; 101: 5087–5088; author reply 88–89.
Pardanini A . JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 2007, 20 Sept; e-pub ahead of print.
Grandage VL, Everington T, Linch DC, Khwaja A . Go6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells. Br J Haematol 2006; 135: 303–316.
Li Z, Xu M, Xing S, Ho WT, Ishii T, Li Q et al. Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. J Biol Chem 2007; 282: 3428–3432.
Giles F, Bergstrom DA, Garcia-Manero G, Kornblau S, Andreeff M, Kantarjian H et al. MK-0457 is a novel aurora kinase and Janus kinase 2 (JAK2) inhibitor with activity in transformed JAK2-positive myeloproliferative disease (MPD). Blood 2006; 108: Abstract no. 4893.
Dobrzanski P, Hexner E, Serdikoff C, Mahfuza J, Swider C, Robinson C et al. CEP-701 is a JAK2 inhibitor which attenuates JAK2/STAT5 signaling pathway and the proliferation of primary cells from patients with myeloproliferative disorders. Blood 2006; 108: Abstract no. 3594.
Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356: 459–468.
Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier I et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996; 88: 1013–1018.
Elliot MA, Verstovsek S, Dingli D, Schwager SM, Mesa RA, Li CY et al. Monocytois is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. Leuk Res 2007; 31: 1503–1509.
Tanimoto TE, Shimoda K, Yamaguchi T, Okamura T, Mizoguchi H, Omine M et al. Prognostic factors in primary chronic myelofibrosis in patients aged less than 70 years: a report on 207 patients with the description of a scoring system and its validation on 100 other patients. Blood 2004; 104: Abstract no. 1524.
Kvasnicka HM, Thiele J, Werden C, Zankovich R, Diehl V, Fischer R . Prognostic factors in idiopathic (primary) osteo-myelofibrosis. Cancer 1997; 80: 708–719.
Thiele J, Kvasnicka HM . Hematopathologic findings in chronic idiopathic myelofibrosis. Semin Oncol 2005; 32: 380–394.
Tefferi A, Dingli D, Li CY, Dewald GW . Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia. Cancer 2005; 104: 1656–1660.
Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912–2919.
We thank the staff of the clinics for providing excellent care of our patients and the medical technicians for their excellent work in the laboratories and Richard Brummel for proof editing.
About this article
Cite this article
Kröger, N., Mesa, R. Choosing between stem cell therapy and drugs in myelofibrosis. Leukemia 22, 474–486 (2008). https://doi.org/10.1038/sj.leu.2405080
- primary myelofibrosis
- myeloproliferative disorders
- allogeneic hematopoietic stem cell transplant
- JAK2 inhibitors
Znaczenie badań molekularnych dla oceny ryzyka i rokowania u chorych na pierwotne włóknienie szpiku w oparciu o wskaźniki prognostyczne IPSS, DIPSS oraz MIPSS
Acta Haematologica Polonica (2018)
Magnetic resonance enterography for assessment of intestinal graft-versus-host disease after allogeneic stem cell transplantation
European Radiology (2015)
Nuclear Medicine and Molecular Imaging (2015)
Assessment of bone marrow inflammation in patients with myelofibrosis: an 18F-fluorodeoxyglucose PET/CT study
European Journal of Nuclear Medicine and Molecular Imaging (2015)